-+ 0.00%
-+ 0.00%
-+ 0.00%

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

Benzinga·03/10/2025 11:10:26
Listen to the news
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.21) per share from the same period last year.